-

Robbins LLP Is Investigating the Officers and Directors of Poseida Therapeutics, Inc. (PSTX) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating whether Poseida Therapeutics, Inc. (NASDAQ: PSTX) and its officers and directors violated securities laws and engaged in unlawful business practices in connection with its initial public offering ("IPO"). Poseida is a clinical-stage biopharmaceutical company that develops therapeutics for patients with high unmet medical needs.

If you have suffered a loss due to Poseida Therapeutics, Inc.'s misconduct, click here.

Poseida conducted its IPO on July 10, 2020, issuing 14 million shares for $16.00 per share. On August 18, 2020, Poseida announced that the U.S. Food and Drug Administration had placed a clinical hold on its Phase 1 clinical trial evaluating the autologous CAR-T therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer due to a patient's death. On this news, Poseida's stock fell 30.31%, to close at $9.06 on August 18, 2020.

Poseida Therapeutics, Inc. (PSTX) Shareholders Have Legal Options

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Poseida settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Reminds Primo Brands Corporation Stockholders on the January 12, 2026 Lead Plaintiff Deadline – Contact us today for information about the PRMB class action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: Company: Primo Brands Corporation (NYSE: PRMB) purports to be a leading North American branded beverage company focused on healthy hydration, offering responsibly sourced products across multiple formats, channels, and price points, and for a wide range of consumer occasions. Its products are distributed in every U.S. state and in Canada. Who is part of the class? The case purportedly represents stockholders who purchased or otherwise acquired (i) the co...

Robbins LLP Reminds Telix Pharmaceuticals Ltd. Stockholders About the January 9, 2026 Lead Plaintiff Deadline – Contact Us Today for Information About the TLX Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: Company: Telix Pharmaceuticals Ltd. (NASDAQ: TLX) is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. What is the class period? February 21, 2025 - August 28, 2025 What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or acquired Telix securities during the class peri...

Robbins LLP Reminds Freeport-McMoran Inc. Stockholders of the January 12, 2026 Lead Plaintiff Deadline – Contact us today for information about the FCX class action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: Company: Freeport-McMoran Inc. (NYSE: FCX) is a mining company. What is the class period? February 15, 2022 - September 24, 2025 What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Freeport during the class period because the Company allegedly misled investors regarding safety at its mines. For more information, submit a form, email attorney Aaron Dumas, Jr....
Back to Newsroom